New York, NYNCT06375044Now EnrollingIRB Ready

Relapsed or Refractory Multiple Myeloma Clinical Trial in New York, NY

Access cutting-edge relapsed or refractory multiple myeloma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access relapsed or refractory multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed or refractory multiple myeloma treatment provided free

Apply for This New York Location

Check if you qualify for this relapsed or refractory multiple myeloma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Relapsed or Refractory Multiple Myeloma Study in New York

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Who Can Participate

Inclusion Criteria

Voluntary participation and signature of informed consent form.
≥18 years of age.
Have documented diagnosis of relapsed or refractory multiple myeloma according to Criteria for Response to Multiple Myeloma Treatment(IMWG)diagnostic criteria who have failed all established standard of care.
Life expectancy ≥12 weeks.
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
Adequate hematologic, hepatic, and renal function.

Exclusion Criteria

Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
Active hepatitis B (HBsAg positive and HBV DNA ≥ 1×104 copies/mL or ≥ 2,000 international unit \[IU\]/mL) or hepatitis C (HCV antibody positive and HCV RNA ≥ ULN) infection; participant with HBsAg positive or detective HBV-DNA at screening should receive antiviral treatment as per local practice during the trial.
Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
Active known or suspected autoimmune disease. Participants with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger, type 1 diabetes mellitus (blood glucose can be controlled by insulin therapy) can be included.
Current or previous other malignancy within 3 years of study entry, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.
Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
Participants with known active infection within 14 days prior to the first SIM0500.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06375044) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed or Refractory Multiple Myeloma Treatment Options in New York, NY

If you're searching for relapsed or refractory multiple myeloma treatment options in New York, NY, this clinical trial (NCT06375044) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed or refractory multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed or refractory multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in New York, NY

See all multiple myeloma clinical trials recruiting in New York — not just this study.

Browse Multiple Myeloma Trials in New York →

Browse More Trials by Condition

Multiple Myeloma TrialsRheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY